ReviewCurrent issues in molecular biology2025
The Role of Methyl Canthin-6-one-2-carboxylate in Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis Treatment.
Review in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Gut-Joint Connection: Microbiome's Role in Rheumatic Disease.Archives of rheumatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovial inflammation, joint destruction, and systemic complications. The nucleotide-binding domain, leucine-rich repeat family, pyrin domain-containing-3 (NLRP3) inflammasome plays a pivotal role in RA pathogenesis by driving the release of pro-inflammatory cytokines and exacerbating oxidative stress. Recent studies identified methyl canthin-6-one-2-carboxylate (Cant) as a potential therapeutic agent that modulates the NLRP3 inflammasome pathway. This review explores the mechanistic role of Cant in RA treatment, particularly its effect on oxidative stress, synovial macrophages, and inflammatory signaling pathways. Additionally, we discuss alternative and complementary approaches, such as gut microbiota modulation and mesenchymal stem cell-based therapies, in the management of RA. Although preliminary findings suggest that Cant exhibits promising anti-inflammatory effects, further preclinical and clinical studies are necessary to validate its therapeutic efficacy. Future research should focus on optimizing dosage, exploring combination therapies, and elucidating the broader implications of targeting the NLRP3 inflammasome for RA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.